Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Gvhd Therapy with Ruxolitinib Is Frequently Associated with Cytopenias, but Significant Decline in Hemoglobin Level Was Only Observed in Non-Responders at Day 28

Stephanie Gergoudis, Sean M. Devlin, Pamela Susman, Amandeep Singh, Stephanie Chinapen, Miguel Angel Perales, Doris M. Ponce

Blood (2024) 144 (Supplement 1): 7349.

https://doi.org/10.1182/blood-2024-210081

Published: 2024

Journal Articles

Efficacy of Budesonide Monotherapy for Low Grade GI Gvhd after Post Transplant Cyclophosphamide

Melinda Cook, Grashma Vadakkel, Stephanie Chinapen, Miguel-Angel Perales, Roni Tamari, Esperanza B. Papadopoulos, Doris M. Ponce, Brian C. Shaffer, Andrew Lin

Blood (2024) 144 (Supplement 1): 7356.

https://doi.org/10.1182/blood-2024-200361

Published: 2024

Journal Articles

Disparities in Microbiota Diversity Impacting Non-European Recipients of 8/8 HLA-Matched Unrelated Donor Transplantation

Natalie Grier Smith, Warren B. Fingrut, Nicholas Waters, Katarina Piasevoli, Teng Fei, John Slingerland, Jonathan U. Peled, Doris M. Ponce

Blood (2024) 144 (Supplement 1): 3498.

https://doi.org/10.1182/blood-2024-212186

Published: 2024

Journal Articles

Optimized Double-Unit Cord Blood Transplantation Mitigates Transplant-Related Mortality Resulting in High Progression-Free Survival in Adults with Hematologic Malignancies

Ioannis Politikos, Sean M. Devlin, Stephanie Chinapen, Sean Quach, Parastoo B. Dahi, Boglarka Gyurkocza, Ann A. Jakubowski, Esperanza B. Papadopoulos, Doris M. Ponce, Roni Tamari, Andromachi Scaradavou, Juliet N Barker

Blood (2023) 142 (Supplement 1): 4916.

https://doi.org/10.1182/blood-2023-190528

Published: 2023

Journal Articles

Topical Ruxolitinib for Chronic Cutaneous GvHD: Promising Results of a Phase 2 Clinical Trial

Alina Markova, Esperanza B. Papadopoulos, Stephen Dusza, Jelena Ostojić, Rizi Ai, Tara Maier, Mario Lacouture, Roni Tamari, Boglarka Gyurkocza, Brian C. Shaffer, Michael Scordo, Miguel-Angel Perales, Andrew Harris, Doris M. Ponce

Blood (2023) 142 (Supplement 1): 777.

https://doi.org/10.1182/blood-2023-182198

Published: 2023

Journal Articles

Trial in Progress: Patient-Reported Outcome Measures in the Prospective Observational Cohort Study of Patients at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Doris M. Ponce, Areej El-Jawahri, Betty K. Hamilton, Nandita Khera, Valkal Bhatt, John Galvin, Catherine J. Lee

Blood (2023) 142 (Supplement 1): 7035.

https://doi.org/10.1182/blood-2023-178073

Published: 2023

Journal Articles

Post-Transplant Pain and Paralysis: Neurologic Amyotrophy As an Atypical Cause of Shoulder Dysfunction Following Hematopoietic Stem Cell Transplant

Chanel Davidoff, Katarzyna Ibanez, Sinchun Hwang, Ilan Goldstein, Darren R. Feldman, Boglarka Gyurkocza, Sergio A. Giralt, Ioannis Politikos, Doris M. Ponce, Michael Scordo, Grigory Syrin, Gunjan L. Shah, Christian M. Custodio, Franchesca Konig

Blood (2023) 142 (Supplement 1): 6978.

https://doi.org/10.1182/blood-2023-189328

Published: 2023

Journal Articles

Use of a Tissue-Targeting Recombinant Human Interleukin-22 Fusion Molecule (F-652) for the Treatment of Advanced Refractory Lower GI Acute Gvhd

Toshihisa Satta, Esperanza B. Papadopoulos, Boglarka Gyurkocza, Pamela Susman, Amandeep Singh, Marco Calafiore, Sergio A. Giralt, Miguel-Angel Perales, Jianmin Chen, Simon Li, Jonathan U. Peled, Marcel R.M. van den Brink, Alan M. Hanash, Doris M. Ponce

Blood (2023) 142 (Supplement 1): 7019.

https://doi.org/10.1182/blood-2023-181269

Published: 2023

Journal Articles

High Progression-Free Survival with Low Relapse Rates after Double-Unit Cord Blood Transplantation in Patients with High-Risk AML

Ioannis Politikos, Warren B Fingrut, Samantha Brown, Stephanie Chinapen, Sean Quach, Parastoo B. Dahi, Boglarka Gyurkocza, Ann A. Jakubowski, Esperanza B. Papadopoulos, Doris M. Ponce, Roni Tamari, Miguel-Angel Perales, Andromachi Scaradavou, Juliet N Barker

Blood (2023) 142 (Supplement 1): 2209.

https://doi.org/10.1182/blood-2023-190836

Published: 2023

Journal Articles

Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

Jonathan U. Peled, Marcel R.M. van den Brink, Doris M. Ponce, Satyajit Kosuri, Nandita Khera, Zachariah DeFilipp, Bina Tejura, David I Lichter, Mary-Jane Lombardo, Meghan Chafee, Jennifer R Wortman, Timothy Straub, Emily Walsh, Augustus Ge, David Lyttle, Brooke Hasson, Christopher Ford, Lisa von Moltke, Matthew Henn

Blood (2023) 142 (Supplement 1): 2198.

https://doi.org/10.1182/blood-2023-188885

Published: 2023

Journal Articles

Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation

Doris M. Ponce, Satyajit Kosuri, Nandita Khera, Zachariah Defilipp, David I Lichter, Jonathan U Peled, Marcel R.M. van den Brink, Kelly Brady, Matthew D Puhl, Gabrielle Glick, Brooke Hasson, Barbara H McGovern, Lisa von Moltke, Bina Tejura

Blood (2023) 142 (Supplement 1): 6994.

https://doi.org/10.1182/blood-2023-180119

Published: 2023

Journal Articles

A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract

Blood (2023) 141 (12): 1389–1401.

https://doi.org/10.1182/blood.2021015111

Published: 2023

Includes: Supplemental data

Journal Articles

Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease

Blood (2022) 140 (22): 2385–2397.

https://doi.org/10.1182/blood.2021015352

Published: 2022

Includes: Supplemental data

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia

Shlomo Elias, Moneeza Walji, Samantha Brown, Sean M. Devlin, Esperanza B. Papadopoulos, Ann A Jakubowski, Doris M Ponce, James W. Young, Sergio A Giralt, Miguel-Angel Perales, Brian C. Shaffer, Parastoo B. Dahi, Richard J. Lin, Christina Cho, Roni Tamari, Melody Smith, Boglarka Gyurkocza

Blood (2022) 140 (Supplement 1): 10627–10628.

https://doi.org/10.1182/blood-2022-170088

Published: 2022

Journal Articles

A Phase 1b Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Stem Cell Transplantation

Doris M Ponce, Jonathan U Peled, Bindu Tejura, Christopher Ford, Marcel R M van den Brink, Mary Jane Lombardo, Satyajit Kosuri, Nandita Khera, Zachariah Defilipp, Lisa von Moltke

Blood (2022) 140 (Supplement 1): 10532–10533.

https://doi.org/10.1182/blood-2022-162386

Published: 2022

Journal Articles

Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

Blood (2022) 140 (Supplement 1): 2137–2139.

https://doi.org/10.1182/blood-2022-157193

Published: 2022

Journal Articles

Post-Transplant Cyclophosphamide Is Associated with Improved Clinical Outcomes in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation

Antonio M. Jimenez, Miguel-Angel Perales, Sean M Devlin, Lazaros J. Lekakis, Craig S. Sauter, Denise Pereira, Amer Beitinjaneh, Samantha Brown, Trent Wang, Doris M Ponce, Mark S. Goodman, Stephanie Chinapen, Krishna V. Komanduri, Brian C Shaffer

Blood (2021) 138 (Supplement 1): 1814.

https://doi.org/10.1182/blood-2021-150714

Published: 2021

Journal Articles

Interim Results of a Pilot, Prospective, Randomized, Double-Blinded, Vehicle- and Comparator-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for Non-Sclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

Alina Markova, Alexander Pan, Stephen Dusza, Arifa Chowdhury, Oluwaseun Kukoyi, Miguel-Angel Perales, Mario Lacouture, Susan Prockop, Doris M Ponce

Blood (2021) 138 (Supplement 1): 3915.

https://doi.org/10.1182/blood-2021-144743

Published: 2021

Journal Articles

Racial Disparities in Access to Alternative Donor Allografts Persist in the Era of "Donors for All"

Warren Fingrut, Ioannis Politikos, Eric Davis, Stephanie Chinapen, Kristine Naputo, Christina Cho, Sergio A Giralt, Boglarka Gyurkocza, Ann A Jakubowski, Esperanza B Papadopoulos, Miguel-Angel Perales, Doris M Ponce, Andromachi Scaradavou, Brian C Shaffer, Juliet N Barker

Blood (2021) 138 (Supplement 1): 423.

https://doi.org/10.1182/blood-2021-147329

Published: 2021

Journal Articles

MAIT and Vδ2 Unconventional T Cells Predict Favorable Outcome after Allogeneic HCT and Are Supported By a Diverse Intestinal Microbiome

Blood (2021) 138 (Supplement 1): 331.

https://doi.org/10.1182/blood-2021-151412

Published: 2021

NARROW

Gvhd Therapy with Ruxolitinib Is Frequently Associated with Cytopenias, but Significant Decline in Hemoglobin Level Was Only Observed in Non-Responders at Day 28

Efficacy of Budesonide Monotherapy for Low Grade GI Gvhd after Post Transplant Cyclophosphamide

Disparities in Microbiota Diversity Impacting Non-European Recipients of 8/8 HLA-Matched Unrelated Donor Transplantation

Optimized Double-Unit Cord Blood Transplantation Mitigates Transplant-Related Mortality Resulting in High Progression-Free Survival in Adults with Hematologic Malignancies

Topical Ruxolitinib for Chronic Cutaneous GvHD: Promising Results of a Phase 2 Clinical Trial

Trial in Progress: Patient-Reported Outcome Measures in the Prospective Observational Cohort Study of Patients at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Post-Transplant Pain and Paralysis: Neurologic Amyotrophy As an Atypical Cause of Shoulder Dysfunction Following Hematopoietic Stem Cell Transplant

Use of a Tissue-Targeting Recombinant Human Interleukin-22 Fusion Molecule (F-652) for the Treatment of Advanced Refractory Lower GI Acute Gvhd

High Progression-Free Survival with Low Relapse Rates after Double-Unit Cord Blood Transplantation in Patients with High-Risk AML

Impact of Investigational Microbiome Therapeutic SER-155 on Pathogen Domination: Initial Results from a Phase 1b Study in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT)

Preliminary Safety Results of the Open-Label Phase of a 2-Part Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Cell Transplantation

A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract

Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease

Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia

A Phase 1b Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of an Investigational Microbiome Therapeutic, SER-155, in Adults Undergoing Hematopoietic Stem Cell Transplantation

Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

Post-Transplant Cyclophosphamide Is Associated with Improved Clinical Outcomes in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation

Racial Disparities in Access to Alternative Donor Allografts Persist in the Era of "Donors for All"

MAIT and Vδ2 Unconventional T Cells Predict Favorable Outcome after Allogeneic HCT and Are Supported By a Diverse Intestinal Microbiome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only